{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:40:06Z","timestamp":1765190406438,"version":"3.46.0"},"reference-count":137,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education under the framework of a \u0141ukasiewicz\u2013Industrial Chemistry Institute","award":["84133301"],"award-info":[{"award-number":["84133301"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The growing number of cancer cases highlights the urgent need to develop new therapies based on effective molecules. Although anticancer activity remains a key element of oncological pharmacology, the importance of agents that support physiological functions and improve the quality of life of cancer patients is also recognised. Compounds that combine these two functions could represent a significant trend in oncology. Moreover, repurposing approved drugs for conditions beyond their original indications could be a promising strategy. An interesting example of this is synthetic flozins (SGLT2 inhibitors), which were originally designed and developed to treat type 2 diabetes mellitus. These compounds contain various aromatic and heteroaryl structures, and changes in these substituents affect the binding strength and therapeutic potency of SGLT2 inhibitors. Beyond their antidiabetic effects, SGLT2 inhibitors exert well-documented cardioprotective and nephroprotective actions, restoring metabolic homeostasis. Given these pleiotropic properties, they could benefit oncology by improving systemic functions and by directly influencing the invasion of cancer cells. This article provides an overview of the use of synthetic flozins in various contexts, with a particular focus on their potential impact on cancer biology and treatment, consolidating their position as multifunctional agents of growing systemic relevance.<\/jats:p>","DOI":"10.3390\/molecules30244681","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:35:51Z","timestamp":1765190151000},"page":"4681","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2621-9838","authenticated-orcid":false,"given":"Micha\u0142","family":"Zieli\u0144ski","sequence":"first","affiliation":[{"name":"Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, \u0141ukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warsaw, Poland"},{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-4223","authenticated-orcid":false,"given":"Olga","family":"Michalak","sequence":"additional","affiliation":[{"name":"Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, \u0141ukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-9843","authenticated-orcid":false,"given":"Magdalena","family":"Ruszczak","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analysis Laboratory, \u0141ukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-9317","authenticated-orcid":false,"given":"Marcin","family":"Cybulski","sequence":"additional","affiliation":[{"name":"Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, \u0141ukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pu\u0219ca\u0219u, C., Zanfirescu, A., Negre\u0219, S., and \u0218eremet, O.C. (2023). Exploring the multifaceted potential of sildenafil in medicine. Medicina, 59.","DOI":"10.3390\/medicina59122190"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","article-title":"Propranolol","volume":"42","author":"Bakheit","year":"2017","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2012.11.017","article-title":"Methotrexate: New therapeutic approaches","volume":"105","author":"Puig","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure\u2014Has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Garofalo, C., Borrelli, S., Liberti, M.E., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., and De Nicola, L. (2019). SGLT2 inhibitors: Nephroprotective efficacy and side effects. Medicina, 55.","DOI":"10.3390\/medicina55060268"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: Insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"zqae008","DOI":"10.1093\/function\/zqae008","article-title":"The Warburg effect reinterpreted 100 yr on: A first-principles stoichiometric analysis and interpretation from the perspective of ATP metabolism in cancer cells","volume":"5","author":"Nath","year":"2024","journal-title":"Function"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhao, J., Jin, D., Huang, M., Ji, J., Xu, X., Wang, F., Zhou, L., Bao, B., Jiang, F., and Xu, W. (2024). Glycolysis in the tumor microenvironment: A driver of cancer progression and a promising therapeutic target. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1416472"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","article-title":"SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK\u2013YAP1 axis","volume":"519","author":"Ren","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium\u2013glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1159\/000536060","article-title":"The clinical relevance of the expression of SGLT2 in lung adenocarcinoma","volume":"102","author":"Iwai","year":"2024","journal-title":"Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","article-title":"An update on the epidemiology of type 2 diabetes: A global perspective","volume":"50","author":"Tinajero","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: Global epidemiology and pathogenesis","volume":"15","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/cas.12043","article-title":"Diabetes mellitus and cancer risk: Review of the epidemiological evidence","volume":"104","author":"Shikata","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/bjc.2014.150","article-title":"Does cancer risk increase with HbA1c, independent of diabetes?","volume":"110","author":"Liebenberg","year":"2014","journal-title":"Br. J. Cancer."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jampilek, J. (2019). Heterocycles in Medicinal Chemistry. Molecules, 24.","DOI":"10.3390\/molecules24213839"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","article-title":"Structural basis of inhibition of the human SGLT2\u2013MAP17 glucose transporter","volume":"601","author":"Niu","year":"2022","journal-title":"Nature"},{"key":"ref_21","unstructured":"National Institute of Diabetes and Digestive and Kidney (2025, November 03). Story of Discovery: SGLT2 Inhibitors: Harnessing the Kidneys to Help Treat Diabetes, Available online: https:\/\/www.niddk.nih.gov\/news\/archive\/2016\/story-discovery-sglt2-inhibitors-harnessing-kidneys-help-treat-diabetes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia","volume":"13","author":"Sarafidis","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.21873\/anticanres.16559","article-title":"Molecular Aspects of C-glycosides: Interactive Analysis of C-linked Compounds with the SGLT2 Molecular Model","volume":"43","author":"Ohkura","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mazoudji, A., and Ecker, G.F. (2025). Docking-Based Classification of SGLT2 Inhibitors. Molecules, 30.","DOI":"10.3390\/molecules30102179"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lloyd, A., Austin-Muttitt, K., and Mullins, J.G.L. (2025). Computational structural studies of SGLT2-related polypharmacy. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0334656"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.56782\/pps.274","article-title":"Advancements in SGLT2 Inhibitors: Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy With a Focus on Pharmacogenomics","volume":"23","author":"Bhagya","year":"2025","journal-title":"Prospect. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acs.oprd.8b00017","article-title":"Synthetic Strategies toward SGLT2 Inhibitors","volume":"22","author":"Aguillon","year":"2018","journal-title":"Org. Process Res. Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.oprd.9b00141","article-title":"A Concise and Efficient Synthesis of Dapagliflozin","volume":"23","author":"Yu","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1021\/ol501755h","article-title":"Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a \u03b2-glycopyranoside","volume":"16","author":"Wang","year":"2014","journal-title":"Org. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/acs.oprd.7b00281","article-title":"Synthesis and Optimization of Canagliflozin by Employing Quality by Design (QbD) Principles","volume":"22","author":"Metil","year":"2018","journal-title":"Org. Process Res. Dev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.joc.5b02734","article-title":"Development of a Scalable Synthesis of Tofogliflozin","volume":"81","author":"Ohtake","year":"2016","journal-title":"J. Org. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1021\/acs.oprd.6b00175","article-title":"A Scalable Synthesis of Tofogliflozin Hydrate","volume":"20","author":"Yang","year":"2016","journal-title":"Org. Process Res. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment","volume":"53","author":"Kakinuma","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3762\/bjoc.13.105","article-title":"A concise and practical stereoselective synthesis of ipragliflozin L-proline","volume":"13","author":"Ma","year":"2017","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/op4002802","article-title":"Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin","volume":"18","author":"Bowles","year":"2014","journal-title":"Org. Process Res. Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pro.2858","article-title":"GLUT, SGLT, and SWEET: Structural and mechanistic investigations of the glucose transporters","volume":"25","author":"Deng","year":"2016","journal-title":"Protein Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00424-020-02433-x","article-title":"Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: From molecular discovery to clinical application","volume":"472","author":"Gyimesi","year":"2020","journal-title":"Pflug. Arch."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kamitori, K., Shirota, M., and Fujiwara, Y. (2022). Structural basis of the selective sugar transport in sodium-glucose cotransporters. J. Mol. Biol., 434.","DOI":"10.1016\/j.jmb.2022.167464"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1073\/pnas.86.15.5748","article-title":"Homology of the human intestinal Na+\/glucose and Escherichia coli Na+\/proline cotransporters","volume":"86","author":"Hediger","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/10600280231211179","article-title":"Sotagliflozin: Efficacy, safety, and potential therapeutic applications in heart failure","volume":"58","author":"Long","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Stielow, M., Fija\u0142kowski, \u0141., Alaburda, A., Grze\u015bk, G., Grze\u015bk, E., Nowaczyk, J., and Nowaczyk, A. (2025). SGLT2 inhibitors: From molecular mechanisms to clinical outcomes in cardiology and diabetology. Molecules, 30.","DOI":"10.3390\/molecules30153112"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_48","first-page":"91622","article-title":"Renal glucosuria in children","volume":"14","author":"Kavukcu","year":"2025","journal-title":"World J. Clin. Pediatr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition: A novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: A systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40264-025-01546-5","article-title":"Investigating risk of cancer with sodium-glucose cotransporter 2 inhibitors: A disproportionality analysis in the WHO global pharmacovigilance database VigiBase\u00ae","volume":"48","author":"Gautier","year":"2025","journal-title":"Drug Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2400797","DOI":"10.1080\/20565623.2024.2400797","article-title":"Relationship between SGLT2 inhibitor use and specific cancer types: A systematic review and meta-analysis","volume":"10","author":"Obaid","year":"2024","journal-title":"Future Sci. OA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13098-025-01898-z","article-title":"Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: A systematic review and meta-analysis","volume":"17","author":"Hajishah","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcph.1722","article-title":"SGLT2 inhibitors and bladder cancer: Analysis of cases reported in the European pharmacovigilance database","volume":"61","author":"Lertxundi","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"110621","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: A systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/DDDT.S469331","article-title":"Cardiotoxicity of anticancer drugs: Molecular mechanisms, clinical management and innovative treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10147-023-02307-z","article-title":"Nephrotoxicity associated with anticancer agents: Perspective on onconephrology from nephrologists","volume":"28","author":"Matsubara","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/SPC.0000000000000544","article-title":"Cardio-oncology: Rationale, aims and future directions","volume":"15","author":"Pan","year":"2021","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_61","first-page":"347","article-title":"Nephro-oncology: Clinical and biochemical aspects of kidney disease and cancer","volume":"70","author":"Lizakowski","year":"2023","journal-title":"Acta Biochim. Pol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hendryx, M., Dong, Y., Ndeke, J.M., and Luo, J. (2022). Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274519"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Flausino, L.E., Carrasco, A.G.M., Furuya, T.K., Tuan, W.J., and Chammas, R. (2025). Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and\/or radiotherapy: A real-world retrospective cohort. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13966-8"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/cac2.70028","article-title":"Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination","volume":"45","author":"Mao","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Karimi, M.A., Khadem, R., Haraj, A., Farahani, M.A., Charehsaz Avari Firouzeh, P., Azizinezhad, A., Raki, H.K., Belbasi, M., Bafrani, M.A., and Deravi, N. (2025). The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: A systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14304-8"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Carrasco","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_70","unstructured":"ClinicalTrials (2025, October 06). gov, Expert Search: SGLT2 the Prevention of Cardiotoxicity, Available online: https:\/\/clinicaltrials.gov\/expert-search?term=SGLT2%20the%20Prevention%20of%20Cardiotoxicity."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.vph.2011.03.005","article-title":"Cellular and molecular mechanisms of vascular injury in diabetes\u2014Part I: Pathways of vascular disease in diabetes","volume":"54","author":"Madonna","year":"2011","journal-title":"Vascul. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: Diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin, a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: A cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(98)00407-0","article-title":"Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death","volume":"32","author":"Haider","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium\u2013glucose cotransporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.urology.2010.11.050","article-title":"Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors","volume":"77","author":"Canter","year":"2011","journal-title":"Urology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e3728","DOI":"10.1097\/MD.0000000000003728","article-title":"Renal function and all-cause mortality risk among cancer patients","volume":"95","author":"Yang","year":"2016","journal-title":"Medicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/IJNRD.S42924","article-title":"Blood oxygenation level-dependent MRI for assessment of renal oxygenation","volume":"7","author":"Neugarten","year":"2014","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium\u2013glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"GBD 2015 Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 377, 13\u201327.","DOI":"10.1056\/NEJMoa1614362"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Singh, G.M., Danaei, G., Farzadfar, F., Stevens, G.A., Woodward, M., Wormser, D., Kaptoge, S., Whitlock, G., Qiao, Q., and Lewington, S. (2013). The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: A pooled analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065174"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014Viewpoint of the IARC working group","volume":"375","author":"Scoccianti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_94","first-page":"123","article-title":"Obesity and lifestyle changes: A global risk factor for cancer","volume":"4","author":"Reddy","year":"2023","journal-title":"Obes. Diabetes Res."},{"key":"ref_95","first-page":"291546","article-title":"Obesity as a major risk factor for cancer","volume":"2013","author":"Silvestris","year":"2013","journal-title":"J. Obes."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11912-010-0139-7","article-title":"Obesity and cancer risk: Recent review and evidence","volume":"13","author":"Chang","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13668-013-0068-9","article-title":"The association between adiposity and breast cancer recurrence and survival: A review of the recent literature","volume":"3","author":"Azrad","year":"2014","journal-title":"Curr. Nutr. Rep."},{"key":"ref_98","first-page":"871","article-title":"Obesity and cancer: The risks, science, and potential management strategies","volume":"19","author":"McTiernan","year":"2005","journal-title":"Oncology"},{"key":"ref_99","first-page":"994","article-title":"Obesity and breast cancer","volume":"25","author":"Ligibel","year":"2011","journal-title":"Oncology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrendo.2014.94","article-title":"Obesity and cancer\u2014Mechanisms underlying tumour progression and recurrence","volume":"10","author":"Park","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Cefalu","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week randomized, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomized, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomized, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Andersen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes","volume":"56","author":"Tosaki","year":"2017","journal-title":"Intern. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: An update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1007\/s11033-023-08525-y","article-title":"Obesity and cancer: Focus on leptin","volume":"50","author":"Ayed","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pflug. Arch."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhou, J., Zhu, J., Yu, S.J., Ma, H.L., Chen, J., Ding, X.F., Chen, G., Liang, Y., and Zhang, Q. (2020). Sodium\u2013glucose co-transporter-2 inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed. Pharmacother., 132.","DOI":"10.1016\/j.biopha.2020.110821"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"eaat5933","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium\u2013glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sabaa, M., Sharawy, M.H., El-Sherbiny, M., Said, E., Salem, H.A., and Ibrahim, T.M. (2022). Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats. Biomed. Pharmacother., 155.","DOI":"10.1016\/j.biopha.2022.113675"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Ali, A., Mekhaeil, B., Biziotis, O.D., Tsakiridis, E.E., Ahmadi, E., Wu, J., Wang, S., Singh, K., Menjolian, G., and Farrell, T. (2023). The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-05289-w"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Abdelhamid, A.M., Saber, S., Youssef, M.E., Gaafar, A.G.A., Eissa, H., Abd-Eldayem, M.A., Alqarni, M., Batiha, G.E.S., Obaidullah, A.J., and Shahien, M.A. (2022). Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed. Pharmacother., 145.","DOI":"10.1016\/j.biopha.2021.112455"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.freeradbiomed.2024.05.018","article-title":"Empagliflozin drives ferroptosis in anoikis-resistant cells by activating miR-128-3p\u2013dependent pathway and inhibiting CD98hc in breast cancer","volume":"220","author":"Nalla","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Murakami, K., Sasaki, Y., Asahiyama, M., Yano, W., Takizawa, T., Kamiya, W., Matsumura, Y., Anai, M., Osawa, T., and Fruchart, J.C. (2022). Selective PPAR\u03b1 modulator pemafibrate and SGLT2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis. Cells, 11.","DOI":"10.3390\/cells11040720"},{"key":"ref_119","first-page":"2797","article-title":"Suppressive effects of the SGLT2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice","volume":"42","author":"Kato","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., and Itoh, M. (2018). Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19658-7"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"16131","DOI":"10.1007\/s00210-025-04098-8","article-title":"Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD\/DEN\/TAA in a rat model: Regulation of AMPK\/HIF-1\u03b1\/YAP-1\/TAZ signaling pathways","volume":"398","author":"Fayed","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e154754","DOI":"10.1172\/JCI154754","article-title":"Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling","volume":"133","author":"Ding","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hamaya, S., Oura, K., Morishita, A., and Masaki, T. (2023). Cisplatin in liver cancer therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310858"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.phrs.2021.105906","article-title":"Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies","volume":"176","author":"Xu","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.freeradbiomed.2023.09.006","article-title":"Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2\u2013c-Myc complex-mediated glutamine starvation","volume":"208","author":"Zeng","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s12276-022-00878-x","article-title":"Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy","volume":"54","author":"Zhou","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Akingbesote, N.D., Norman, A., Zhu, W., Halberstam, A.A., Zhang, X., Foldi, J., Lustberg, M.B., and Perry, R.J. (2022). A precision medicine approach to metabolic therapy for breast cancer in mice. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03422-9"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Nakachi, S., Okamoto, S., Tamaki, K., Nomura, I., Tomihama, M., Nishi, Y., Fukushima, T., Tanaka, Y., Morishima, S., and Imamura, M. (2022). Impact of anti-diabetic sodium\u2013glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112864"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e154515","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Nakano, D., Kawaguchi, T., Iwamoto, H., Hayakawa, M., Koga, H., and Torimura, T. (2020). Effects of canagliflozin on growth and metabolic reprogramming in hepatocellular carcinoma cells: Multi-omics analysis (IMPAQT). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232283"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","article-title":"AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo","volume":"17","author":"Faubert","year":"2013","journal-title":"Cell Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","article-title":"Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK","volume":"43","author":"Shoda","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","article-title":"An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit migration and induce apoptosis of cervical carcinoma cells","volume":"495","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Jeng, K.S., Chang, C.F., and Lin, S.S. (2020). Sonic hedgehog signaling in organogenesis, tumors, and tumor microenvironments. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030758"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Okada, J., Yamada, E., Saito, T., Yokoo, H., Osaki, A., Shimoda, Y., Ozawa, A., Nakajima, Y., Pessin, J.E., and Okada, S. (2020). Dapagliflozin inhibits cell adhesion to collagen I and IV and increases ectodomain proteolytic cleavage of DDR1 by increasing ADAM10 activity. Molecules, 25.","DOI":"10.3390\/molecules25030495"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","article-title":"SGLT2 inhibitor activates the STING\/IRF3\/IFN-\u03b2 pathway and induces immune infiltration in osteosarcoma","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med. Sci. Monit."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/24\/4681\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:36:50Z","timestamp":1765190210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/24\/4681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":137,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["molecules30244681"],"URL":"https:\/\/doi.org\/10.3390\/molecules30244681","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}